Hikma Pharmaceuticals Patent-Cliff Exposure & CMS Drug Spending Portfolio

Hikma Pharmaceuticals (Berkeley Heights, NJ): 57 reconciled FDA prescription therapies, $1.42B 2024 CMS Part D & Medicaid spend, and 56 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterBerkeley Heights, NJ
Reconciled FDA Portfolio Therapies57
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2033-01-01
2024 CMS Total Public Spend$1.42B
2024 Medicare Part D Spend$712.0M
2024 Medicaid Spend$704.1M
California HCAI SB 17 Filings56 WAC filings (max 2368.3% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Hikma Pharmaceuticals across sibling Meru public-data platforms.